Download PDF
Digestive Disease Interventions 2019; 03(01): 063-070
DOI: 10.1055/s-0038-1675757
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Systemic Therapy for Neuroendocrine Neoplasms

David L. Chan
1   Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
2   Northern Clinical School, Faculty of Medicine, University of Sydney, NSW, Australia
,
Simron Singh
3   Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
4   Department of Medicine, University of Toronto, Toronto, Ontario, Canada
› Author Affiliations
Further Information

Publication History

19 July 2018

11 September 2018

Publication Date:
04 February 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Neuroendocrine neoplasms (NENs) are heterogeneous malignancies which are becoming more common. Systemic treatment is considered for patients with advanced disease, and treatment decisions are often driven by the histological grade of the tumor and the site of primary. Somatostatin analogues are the first-line option of choice for gastroenteropancreatic NENs but subsequent options may include the targeted agents everolimus and sunitinib as well as peptide receptor radionuclide therapy. Telotristat is a new option for the treatment of refractory carcinoid syndrome diarrhea. Chemotherapy is infrequently used for Grade 1 to 2 NENs (except for the combination of capecitabine and temozolomide) but is the mainstay of therapy for Grade 3 neuroendocrine carcinomas. Bronchial NENs are graded differently and there are few proven options for systemic treatment. Optimal integration of available systemic therapies, the timely recognition of tumor heterogeneity, and the use of nuclear medicine are areas of ongoing research. Finally, the patient experience is impacted by factors such as delayed diagnosis and symptoms of carcinoid syndrome. Clinicians need to account for patient priorities and disease characteristics to individualize therapy choices for patients with advanced NEN.

Keywords

neuroendocrine tumors - somatostatin - everolimus - PRRT - neuroendocrine carcinomas
 

  • References

  • 1 Dasari A, Shen C, Halperin D. , et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
    CrossrefPubMedGoogle Scholar
  • 2 Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121 (04) 589-597
    CrossrefPubMedGoogle Scholar
  • 3 Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer 2018; 124 (04) 807-815
    CrossrefPubMedGoogle Scholar
  • 4 Basturk O, Yang Z, Tang LH. , et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39 (05) 683-690
    CrossrefPubMedGoogle Scholar
  • 5 Tang LH, Untch BR, Reidy DL. , et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 2016; 22 (04) 1011-1017
    CrossrefPubMedGoogle Scholar
  • 6 Halperin DM, Shen C, Dasari A. , et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017; 18 (04) 525-534
    CrossrefPubMedGoogle Scholar
  • 7 Gustafsson BI, Tømmerås K, Nordrum I. , et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 111 (12) 1517-1522
    CrossrefPubMedGoogle Scholar
  • 8 Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012; 41 (03) 461-466
    CrossrefPubMedGoogle Scholar
  • 9 Pellikka PA, Tajik AJ, Khandheria BK. , et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87 (04) 1188-1196
    CrossrefPubMedGoogle Scholar
  • 10 Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5 (10) 1502-1522
    CrossrefPubMedGoogle Scholar
  • 11 Rinke A, Müller HH, Schade-Brittinger C. , et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27 (28) 4656-4663
    CrossrefPubMedGoogle Scholar
  • 12 Caplin ME, Pavel M, Ćwikła JB. , et al; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371 (03) 224-233
    CrossrefPubMedGoogle Scholar
  • 13 Wolin EM, Jarzab B, Eriksson B. , et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015; 9 (Sep): 5075-5086
    PubMedGoogle Scholar
  • 14 Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine 2017; 57 (03) 366-375
    CrossrefPubMedGoogle Scholar
  • 15 Ghia J-E, Li N, Wang H. , et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009; 137 (05) 1649-1660
    CrossrefPubMedGoogle Scholar
  • 16 Savelieva KV, Zhao S, Pogorelov VM. , et al. Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS One 2008; 3 (10) e3301
    CrossrefPubMedGoogle Scholar
  • 17 Cremata Jr VY, Koe BK. Clinical and biochemical effects of fenclonine: a serotonin depletor. Dis Nerv Syst 1968; 29 (05) 147-152
    PubMedGoogle Scholar
  • 18 Kulke MH, Hörsch D, Caplin ME. , et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol 2017; 35 (01) 14-23
    PubMedGoogle Scholar
  • 19 Scarpa A, Chang DK, Nones K. , et al; Australian Pancreatic Cancer Genome Initiative. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017; 543 (7643): 65-71
    CrossrefPubMedGoogle Scholar
  • 20 Yao JC, Shah MH, Ito T. , et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364 (06) 514-523
    CrossrefPubMedGoogle Scholar
  • 21 Yao JC, Fazio N, Singh S. , et al; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387 (10022): 968-977
    CrossrefPubMedGoogle Scholar
  • 22 Raymond E, Dahan L, Raoul JL. , et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364 (06) 501-513
    CrossrefPubMedGoogle Scholar
  • 23 Strosberg J, El-Haddad G, Wolin E. , et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 24 Strosberg J, Wolin E, Chasen B. , et al; NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018; 36 (25) 2578-2584
    CrossrefPubMedGoogle Scholar
  • 25 Wong MH, Chan DL, Lee A. , et al. Systematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET). PLoS One 2016; 11 (06) e0158140
    CrossrefPubMedGoogle Scholar
  • 26 Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang Y-Z, Woltering EA. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist 2016; 21 (06) 671-675
    CrossrefPubMedGoogle Scholar
  • 27 Cives M, Ghayouri M, Morse B. , et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23 (09) 759-767
    CrossrefPubMedGoogle Scholar
  • 28 Fine RL, Gulati AP, Krantz BA. , et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013; 71 (03) 663-670
    CrossrefPubMedGoogle Scholar
  • 29 Kunz PL, Catalano PJ, Nimeiri H. , et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol 2018; 36 (15_suppl): 4004
    CrossrefPubMedGoogle Scholar
  • 30 Hegi ME, Diserens A-C, Gorlia T. , et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352 (10) 997-1003
    CrossrefPubMedGoogle Scholar
  • 31 Faiss S, Pape U-F, Böhmig M. , et al; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21 (14) 2689-2696
    CrossrefPubMedGoogle Scholar
  • 32 Mirvis E, Mandair D, Garcia-Hernandez J, Mohmaduvesh M, Toumpanakis C, Caplin M. Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study. Anticancer Res 2014; 34 (11) 6601-6607
    PubMedGoogle Scholar
  • 33 Pavel M, O'Toole D, Costa F. , et al; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103 (02) 172-185
    CrossrefPubMedGoogle Scholar
  • 34 Yao JC, Guthrie KA, Moran C. , et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017; 35 (15) 1695-1703
    CrossrefPubMedGoogle Scholar
  • 35 Mitry E, Walter T, Baudin E. , et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. Eur J Cancer 2014; 50 (18) 3107-3115
    CrossrefPubMedGoogle Scholar
  • 36 Sorbye H, Welin S, Langer SW. , et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24 (01) 152-160
    CrossrefPubMedGoogle Scholar
  • 37 Yamaguchi T, Machida N, Morizane C. , et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014; 105 (09) 1176-1181
    CrossrefPubMedGoogle Scholar
  • 38 Kunz PL, Reidy-Lagunes D, Anthony LB. , et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42 (04) 557-577
    CrossrefPubMedGoogle Scholar
  • 39 Hentic O, Hammel P, Couvelard A. , et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012; 19 (06) 751-757
    CrossrefPubMedGoogle Scholar
  • 40 Hadoux J, Malka D, Planchard D. , et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015; 22 (03) 289-298
    CrossrefPubMedGoogle Scholar
  • 41 Kashyap R, Hofman MS, Michael M. , et al. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015; 42 (02) 176-185
    CrossrefPubMedGoogle Scholar
  • 42 Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013; 501 (7467): 355-364
    PubMedGoogle Scholar
  • 43 Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501 (7467): 328-337
    CrossrefPubMedGoogle Scholar
  • 44 Deppen SA, Blume J, Bobbey AJ. , et al. 68Ga-DOTATATE compared with 111in-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med 2016; 57 (06) 872-878
    CrossrefPubMedGoogle Scholar
  • 45 Panagiotidis E, Alshammari A, Michopoulou S. , et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med 2017; 58 (01) 91-96
    CrossrefPubMedGoogle Scholar
  • 46 Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med 2012; 14 (74) 71-81
    PubMedGoogle Scholar
  • 47 Singh S, Granberg D, Wolin E. , et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol 2016; 3 (01) 43-53
    PubMedGoogle Scholar
  • 48 Townsend A, Price T, Yeend S, Pittman K, Patterson K, Luke C. Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol 2010; 44 (03) 195-199
    CrossrefPubMedGoogle Scholar
  • 49 Singh S, Law C. Multidisciplinary reference centers: the care of neuroendocrine tumors. J Oncol Pract 2010; 6 (06) e11-e16
    CrossrefPubMedGoogle Scholar
  • 50 Thawer A, Chan DL, Leake J, Dias S, Singh S. Pharmacist-led development of AE Management Algorithm for Oral Therapies in NETs. In: NANETS Symposium 2017 . p. Abstract C-37
    PubMedGoogle Scholar
  • 51 Mehnert JM, Rugo HS, O'Neil BH. , et al. 427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study. Ann Oncol [Internet]. 2017 Sep 1;28(5_suppl). Available from: http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368/4108699/427OPembrolizumab-for-patients-with-PDL1positive
    PubMedGoogle Scholar
  • 52 Iyer RV, Konda B, Owen DH. , et al. Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors. J Clin Oncol 2018; 36 (15_suppl): 4105
    CrossrefPubMedGoogle Scholar